SUMMARY
This study investigates molecular and cellular mechanisms involved in mesenchymal stem cell (MSC)-mediated modulation of IL-17 signaling during liver fibrosis. Mice received CCl 4 (1 ll/g intraperitoneally) twice/ week for 1 month. MSCs (1 9 10 6 ), or MSC-conditioned medium (MSC-CM), were intravenously injected 24 h after CCl 4 and on every 7th day. Liver fibrosis was determined by macroscopic examination, histological analysis, Sirius red staining, and RT-PCR. Serum levels of cytokines, indoleamine 2,3-dioxygenase (IDO), and kynurenine were determined by ELISA. Flow cytometry was performed to identify liver-infiltrated cells. In vitro, CD4 + T cells were stimulated and cultured with MSCs. 1-methyltryptophan was used for inhibition of IDO. MSCs significantly attenuated CCl 4 
Introduction
Interleukin (IL)-17 plays an important pro-fibrogenic role in hepatic fibrosis [1, 2] . During chronic liver inflammation, IL-17 is mainly produced by liver-infiltrated Th17 cells which are in increased number present in livers of patients suffering from hepatic fibrosis, developed after alcohol-induced liver injury, autoimmune, acute, and chronic hepatitis [3] [4] [5] [6] . IL-17, produced by Th17 cells, stimulates hepatic stellate cells (HSCs) to increase synthesis of collagen-1, a-smooth muscle actin (a-SMA), and transforming growth factor (TGF)-b1 and promote liver fibrosis [1, 7] . Mice deficient in IL-17 are resistant to liver fibrosis [1, 2] suggesting that therapeutic approaches which attenuate IL-17 production in liver would have beneficent effects in the therapy of hepatic fibrosis.
Advanced IL-17-driven liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation. However, liver transplantation has several limitations, including lack of donors, complications of surgical interventions, side effects of immunosuppressive drugs, and high medical costs. Accordingly, the alternative approaches, such as stem cell transplantation, have been suggested as an effective alternate therapy to liver transplantation [8] .
Among stem cells, mesenchymal stem cells (MSCs) are due to their immunomodulatory ability and capacity for differentiation into hepatocytes, tested in many preclinical and clinical studies as possible new therapeutic agents for the treatment of acute and chronic liver diseases including fibrosis [9, 10] . MSCs can alter immune response and regulate the proliferation, activation, and effector function of all immune cells, including CD4 + helper and CD8 + cytotoxic T lymphocytes [11] . MSC-induced suppression of T cells is mediated through cell-to-cell contact and through the production of soluble factors [11, 12] . Interaction between inhibitory molecule programmed death 1 (PD-1), with its ligands (PD-L1 and PD-L2), is responsible for MSC-dependent inhibition of T cells mediated by cell-tocell contact [13] . Among soluble factors, indoleamine 2,3-dioxygenase (IDO) is the most important for suppression of effector T cells by human MSCs [14] . IDO promotes the degradation of tryptophan into kynurenine and toxic metabolites (quinolinic acid and 3-hydroxy-anthranilic acid) which suppress proliferation or induce apoptosis of activated T cells.
Although it is known that MSCs may attenuate chronic liver inflammation and are able to suppress proliferation of Th1 cells, their capacity to modulate function of Th17 cells in hepatic fibrosis, is still unknown.
Using well-established murine model of liver fibrosis, induced by carbon tetrachloride (CCl 4 ), we investigated molecular and cellular mechanisms involved in MSCmediated modulation of IL-17 signaling during the pathogenesis of liver fibrosis. Herewith, we provide the evidence that MSCs attenuate liver fibrosis by reducing liver infiltration of Th17 cells in IDO-dependent manner.
Materials and methods

Cells
Mouse MSCs isolated from bone marrow of C57Bl/6 mice were purchased from Gibco (Catalog No. S10502-01). Mouse fibroblasts (STO cells) were purchased from American Type Culture Collection (Catalog No. CRL-1503). MSCs and STO cells (passage 6) were cultured in complete Dulbecco's Modified Eagle Medium (DMEM) under standard conditions. MSC-conditioned medium (MSC-CM) was generated as previously described [15] .
Animals
Eight-to ten-week-old male wild-type C57Bl/6 mice were used. All animals received humane care, and all experiments were approved by and conducted in accordance with the Guidelines of the Animal Ethics Committee of the Faculty of Medical Sciences, University of Kragujevac, Serbia.
Induction of liver fibrosis
Mice received CCl 4 /corn oil [ratio 1:3; 1 ll/g intraperitoneally (i.p.); Sigma-Aldrich, St-Louis, MO, USA] twice per week for 1 month [16] . Mice were sacrificed 1 week after the last CCl4/corn oil challenge.
Administration of MSCs or STO cells
6 MSCs or STO cells were intravenously (i.v.) injected via the tail vein 24 h after the first administration of CCl 4 /corn oil and on 7th, 14th, and 21st day of experiment [17] .
Pharmacological inhibition of IDO
Mesenchymal stem cells were cultured for 48 h in culture medium containing 1 mM 1-methyltryptophan, (1-MT; Sigma-Aldrich), an inhibitor of IDO activity [18] . CCl 4 /corn oil and CCl 4 /corn oil + MSC-treated mice continuously received 1-MT (2 mg/ml in drinking water) for in vivo inhibition of IDO activity [19] .
Transplantation of MSCs in established CCl 4 -induced liver fibrosis
One week after the last injection of CCl 4 /corn oil, mice i.v. received either 1 9 10 6 MSCs or saline once per week for next 3 weeks.
Histopathological analyses
Histological analysis of liver injury was performed as previously described [20] . Quantification of fibrosis in mouse liver sections stained with PicroSirius red (109) was performed using IMAGEJ software (National Institutes of Health, Bethesda, MD, USA), on 10 fields/section, as described [21] .
Measurements of cytokines in serum
The commercial enzyme-linked immunosorbent (ELISA) sets (R&D Systems, Minneapolis, MN, USA) were used to measure concentration of IL-17 and IL-10 according to the manufacturer's instructions [22] .
Measurement of IDO in serum
Indoleamine 2,3-dioxygenase content was determined in mice sera using mouse IDO specific ELISA kit (Catalog No. MI0064; NeoBioLab, Cambridge, MA, USA).
Detection of kynurenine
As IDO catalyzes the metabolism of tryptophan in the kynurenine pathway, IDO activity in serum of control, CCl 4 and CCl 4 +MSC-treated mice was determined by spectrophotometric assay for kynurenine [18] .
Isolation of liver-infiltrated immune cells and analysis with flow cytometry
Mononuclear cells (MNCs) were removed from liver of each mouse and analyzed by flow cytometry, as described previously [23] .
Detection of MSCs in the livers of CCl 4 -treated mice
Mesenchymal stem cells were fluorescence-labeled using pre-incubation with carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Thermo Fisher Scientific, Stockholm, Sweden) according to the manufacturer's instructions, as described [24] . For homing assays, 1 9 10 6 CFSE-labeled MSCs were injected into the tail veins of mice 24 h after the first administration of CCl 4 /corn oil and on 7th, 14th, and 21st day of experiment. Single cell suspensions were prepared from liver tissues on 2nd, 11th, 18th, and 27th day of the experiment and analyzed by flow cytometry. Absolute numbers of homed MSCs per organ were calculated according to the formula n = m g /m a 9 v 1 /v 2 9 100 000/x, with m g indicating total mass of the organ analyzed; m a , mass of the analyzed proportion of the organ; v 1 , total volume in which the entire organ-cell suspension was contained; v 2 , volume of sample aspirated/analyzed; x, number of positive events acquired per 100 000 events, as described [25] .
Isolation of CD4
+ cells CD4 + cells were isolated from hepatic MNCs by magnetic cell sorting (Miltenyi Biotec, Bergisch Gladbach, Germany), according to manufacturer's instructions, as described [26] .
Co-culture of CD4 + cells and MSCs in vitro CD4 + cells, in vitro stimulated with concanavalin A (2.5 lg/ml) [27] and IL-2 (50 ng/ml) [28] , were cultured alone, in direct contact with MSCs (ratio 10:1), or physically separated from MSCs by 0.4 lm porous transwell system (Corning Incorporated; Life Sciences, Chorges, France). CD4 + T lymphocytes were placed in the lower chamber, and MSCs were seeded in the transwell inserts, at ratio 10:1, as described previously [29] . After 48 h of culture, supernatants were collected and frozen at À20°C until cytokine concentrations were measured by ELISA kits (R&D Systems).
Isolation of hepatic stellate cells
Hepatic stellate cells were isolated from the mouse liver as described previously [30, 31] . Isolated HSCs were then used in the co-culture experiments.
Co-culture of MSC-primed CD4 + cells and HSCs
Mesenchymal stem cells, cultured in the complete medium in the presence or in the absence of 1 mM 1-MT, were seeded in 0.4 lm porous transwell system with in vitro stimulated CD4 + cells (ratio 10:1) [29] . After 48 h, CD4 + cells were harvested and cultured with HSCs (ratio 20:1) for additional 48 h [32] . The expression of collagen-1 in HSCs was evaluated by real-time PCR analysis.
RNA isolation and real-time PCR analysis
Total RNA from livers and HSCs was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The fold change of mRNA gene expression for collagen-1, a-SMA, TGF-b, and b-actin as a housekeeping gene (Invitrogen) was calculated as described [33] .
Biostatistics
Statistical analysis was performed using SPSS 20.0. Data are presented as means AE SEM (standard error of the mean). Statistical significance was determined by Student t-test and, where appropriate, using
Mann-Whitney U-test. Statistical significance was assumed at P < 0.05.
Results
Intravenously injected MSCs migrate in the CCl 4 -injured livers and ameliorate fibrosis
It is well known that intravenously injected MSCs migrate into livers [25] and that tissue damage and inflammation enhance the efficacy of their homing [34] . Accordingly, 24 h after intravenous injection, MSCs were detected in CCl 4 -injured livers and their presence in damaged livers had been increasing after each application (Fig. 1a) . Mesenchymal stem cells managed to significantly attenuate CCl 4 -induced liver fibrosis, as determined by macroscopic examination (Fig. 1b) , histological analysis ( Fig. 1c) , Sirius red staining (Fig. 1d) , and quantitative RT-PCR (Fig. 1g ).
An irregular contour with one or several nodules was found macroscopically on the surface of the livers of CCl 4 -treated mice (Fig. 1b) . On contrary, livers obtained from CCl 4 +MSC-treated mice had a smooth surface with uniform and soft textures, similar to the livers of control animals ( Fig. 1b) , indicating that CCl 4 -induced macroscopic changes were significantly attenuated in MSC-treated animals.
H&E staining of liver tissues obtained from CCl 4 -treated mice revealed damage of liver cells and centrilobular congestion with infiltration of inflammatory cells. Specifically, single cell necrosis and ballooning degeneration of hepatocytes were observed in central and midlobular regions (Fig. 1c , black arrows), often associated with fibrosis and inflammatory cell infiltration. Organized hepatic architecture was replaced by regenerative nodules connected with fibrous septa. On contrary, there were only several solitary areas of necrotic tissue in CCl 4 -treated mice that received MSCs resulting with significantly reduced total size of liver fibrosis (Fig. 1c) .
Sirius red staining of liver tissues obtained from CCl 4 -treated mice revealed extensive collagen deposition and pseudolobular formation (Fig. 1d , black arrows), suggesting development of liver fibrosis. MSCs treatment resulted in a remarkable reduction in the size of the stained area of fibrous dense tissue (Fig. 1d) .
In line with these findings, percentage of fibrotic liver tissue (P = 0.007, Fig. 1e ) and increase of AST and ALT levels (P = 0.038 for AST and P = 0.043 for ALT, Fig. 1f ) were significantly lower in CCl 4 +MSC-treated mice compared to mice that received CCl 4 only.
In accordance with the histological and biochemical analysis, quantitative RT-PCR showed that MSC treatment significantly decreased expression of pro-fibrogenic markers: collagen-1 (P = 0.043) and a-SMA (P = 0.034) as well as TGF-b (P = 0.036) known as major pro-fibrogenic cytokine associated with organ fibrogenesis [1, 7] (Fig. 1g) .
Attenuation of liver fibrosis was not noticed in CCl 4 -treated mice that received STO cells (Fig. 1b-g ), confirming specificity of MSC-based beneficent effects.
Importantly, MSCs efficiently attenuated completed CCl 4 -induced liver fibrosis, as well (Fig. S1 ), confirming their therapeutic potential. To dissect out cellular target of MSC-dependent modulation of liver fibrosis, flow cytometry analysis of liver-infiltrated MNCs was performed. Intracellular staining of liver infiltrating MNCs revealed significantly lower number of IL-17-producing CD4 + T cells (P = 0.009, Fig. 2c ) and significantly higher number of IL-10-producing CD4 + T lymphocytes (P = 0.024, Fig. 2d ) in CCl 4 +MSC-treated mice compared to animals treated with CCl 4 only. On contrary, there was no significant difference in the total number of liver infiltrating IL-17-producing CD8 + T lymphocytes between these groups (Fig. 2e) suggesting that CD4 + T cells were major targets of MSC-mediated modulation of IL-17 production in liver-infiltrated T cells.
MSCs suppress Th17 cells in paracrine manner
To investigate whether cell-to-cell contact was required for MSC-dependent suppression of liver-infiltrated Th17 lymphocytes, MSCs and liver CD4 + T cells were cultured with or without transwell systems, which was used to separate cells by a membrane permeable to soluble molecules.
Intracellular staining revealed significantly lower number of IL-17 producing in vitro activated liver CD4 + T cells, cultured with MSCs in transwell system, when compared to stimulated CD4 + T lymphocytes that were culture without MSCs (P = 0.003, Fig. 3a left panel) . On contrary, MSC-derived products induced significant increase in total number of IL-10 producing In line with these findings, significantly lower expression of collagen-1 (P = 0.001, Fig. 3b ) was noticed in HSCs that were cultured with MSC-primed liver CD4
+ T cells when compared with HSCs which were cultured with MSC+1-MT-primed liver CD4 + T cells, confirming the importance of IDO for MSCdependent modulation of CD4 + T-cell capacity for HSC activation.
MSC-CM-mediated proliferation of IL-10 producing CD4 + T cells and suppression of Th17 cells was abrogated by IDO inhibitor
In line with results obtained in vitro, injection of MSC-CM significantly down-regulated serum levels of liver enzymes (Fig. 3c , P = 0.037 for AST; P = 0.042 for ALT) and cytokine production in liver-infiltrated CD4 + T cells (Fig. 3d) , indicating that MSCs attenuate IL-17-driven liver fibrosis in paracrine manner.
Intracellular staining of liver immune cells revealed that MSC-CM treatment managed to significantly reduce infiltration of IL-17 producing CD4 + T cells (P = 0.004, Fig. 3d upper panel) and to significantly increase percentage of IL-10 producing T cells (P = 0.031, Fig. 3d lower panel) in livers of CCl 4 -treated mice. This was accompanied with decreased serum levels of pro-fibrogenic IL-17 (P = 0.028, Fig. 3e left panel) and elevated serum levels of hepatoprotective IL-10 (P = 0.042, Fig. 3e right panel) .
Importantly, 1-MT completely diminished antifibrotic and immunomodulatory effects of MSC-CM. Injection of MSC-CM that contained 1-MT did not attenuate liver enzymes (Fig. 3c) and IL-17 in sera (Fig. 3e left  panel) and did not increase serum levels of IL-10 ( Fig. 3e right panel) . In line with these findings, IDO inhibition reduced capacity of MSC-CM to increase percentage of IL-10 producing CD4 + T cells in the fibrotic livers (P = 0.048, Fig. 3d lower panel) . Moreover, total number of IL-17 producing CD4 + T cells in CCl 4 +MSC-CM+1-MT was significantly higher when compared to CCl 4 +MSC-CM-treated mice (P = 0.02, Fig. 3d upper panel) , indicating that MSC-mediated attenuated infiltration of Th17 cells in the fibrotic liver is IDO-dependent.
In line with these findings are data obtained from CCl 4 +MSC-treated mice in which IDO activity was inhibited in vivo (Fig. 4) . Macroscopic examination, histological analysis, and Sirius red staining revealed significant differences between CCl 4 +MSC and CCl 4 1-MT +MSC-treated animals (Fig. 4a-c) . Significantly higher percentage of fibrotic tissue (P = 0.001, Fig. 4d ), elevated serum levels of AST and ALT (Fig. 4e , P = 0.001 for AST; P = 0.006 for ALT), increased concentration of IL-17 in sera (P = 0.001, Fig. 4g ), and increased number of liver-infiltrated IL-17 producing CD4 + T cells (P = 0.003, Fig. 4h ), decreased serum concentration of IL-10 (P = 0.033, Fig. 4g ), and significantly lower number of liver-infiltrated IL-10-producing CD4 + T cells were observed in CCl 4 +MSC-treated mice in which IDO activity was inhibited in vivo when compared with CCl 4 +MSC-treated animals, confirming the importance of IDO for MSC-dependent attenuation of CCl 4 -induced liver fibrosis.
Discussion
Th17 cells play an active and important role in liver fibrosis [1, 2] . IL-17, produced by Th17 cells, directly stimulates HSCs to express collagen-1 and promotes their activation into fibrogenic myofibroblasts, directly contributing to the development and progression of liver fibrosis [1] . Increased expression of IL-17 was detected in livers of patients with hepatic fibrosis and correlated with increased numbers of circulating Th17 cells and with the severity of disease [1] , suggesting IL-17 and Th17 cells as an attractive target for antifibrotic therapy.
Herewith, we demonstrated that transplantation of MSCs as well as injection of MSC-CM reduces liver infiltration of Th17 cells resulting with attenuation of liver fibrosis (Figs. 1 and 3) . Decreased serum levels of IL-17 ( Fig. 2a) and reduced number of Th17 in the livers (Fig. 2c) , noticed in CCl 4 +MSC-treated mice, correlated with decreased expression of HSC-derived fibrotic markers: collagen-1, a-SMA, and TGF-b (Fig. 1g) . Additionally, MSCs managed to reduce established CCl 4 -induced liver fibrosis (Fig. S1 ), indicating efficacy of MSC-based therapy for the treatment of liver fibrosis.
During the progression of liver fibrosis, IL-10 producing CD4 + T cells have been recruited to the liver where they suppress hepatic inflammation [35] . Dynamic changes in the frequencies of IL-17 and IL-10 producing CD4 + T cells significantly affect outcome of chronic liver injury [7] , and their imbalance is usually linked to the progression of inflammation and fibrosis [7, 36] . Herewith we showed that MSC-dependent suppression of Th17 cells in the liver was accompanied with elevated serum levels of immunosuppressive IL-10 ( Fig. 2a) followed with an increased percentage of hepato-protective IL-10 producing CD4 + T cells (Fig. 2d ) indicating that beneficent effects of MSCs in CCl 4 -induced fibrosis were closely related to the modulation of the balance between IL-17 and IL-10 producing CD4 + T cells within liver. Interestingly, serum concentration of IL-10 in control (corn oil-untreated mice) was lower than those measured in corn oil and corn oil + MSC-treated animals, while percentage of IL-10 producing CD4 + T cells were similar between these groups. IL-10, one of the most important immunoregulatory and anti-inflammatory cytokines, is produced by CD4 + T cells, alternatively activated macrophages and MSCs. MSCs may produce IL-10 even in the absence of fibrosis, after stimulation by IL-10-inducing factors, such as corn oil. As corn oil potentiates production of IL-10 in macrophages [37, 38] , we assumed that the higher serum concentration of IL-10, noticed in corn oil-treated mice compared to corn oil-untreated mice was a consequence of corn oilinduced increased production of IL-10 in macrophages and that this difference was not related to the production of IL-10 in CD4 + T cells. Similar as transplanted MSCs, injection of MSC-CM managed to efficiently attenuate liver fibrosis (Fig. 3c-e) . The importance of MSC-CM-mediated beneficial effects in attenuation of CCl 4 -induced fibrosis is an important finding having in mind that engrafted MSCs could be a major source of functional myofibroblasts which have detrimental effects in liver fibrosis [39] . After intrahepatic injection, MSCs permanently remain in the injured livers and can differentiate into myofibroblasts rather than in hepatocytes [40, 41] .
Mesenchymal stem cell-CM-mediated attenuation of CCl 4 -induced fibrosis was accompanied with reduced number of liver-infiltrated Th17 cells and increased percentage of IL-10 producing CD4 + T cells in the fibrotic livers (Fig. 3d) , decreased serum level of IL-17 and increased serum concentration of IL-10 ( Fig. 3e) , indicating that MSC modulate cytokine production of CD4 + T lymphocytes, through the release of soluble factors.
Among MSC-derived products, IL-6, insulin-like growth factor binding protein-2 (IGFBP-2), IL-1 receptor antagonist (IL-1Ra), hepatocyte growth factor (HGF), neural growth factor (NGF), IL-10, and TGF-b3 may contribute to the beneficent effects of MSCs in the attenuation of liver fibrosis [42] [43] [44] [45] . MSC-derived IL-6 has anti-apoptotic effects, IGFBP-2 regulates insulin-like growth factor-I that has fibrinolytic activity while IL-1 Ra, as natural inhibitor of pro-inflammatory IL-1, is involved in MSC-dependent suppression of inflammation [42] . MSC-produced HGF and NGF promote apoptosis of HSCs, while IL-10 and TGF-b3 are responsible for MSC-dependent suppression of collagen synthesis in HSCs [43] [44] [45] . Additionally, MSCs can regulate the expression of matrix metalloproteinase (MMP)-9 that has been associated with resolution of liver fibrosis [46] .
Among all MSC-derived soluble molecules, IDO plays the most important role in MSC-mediated suppression of IL-17 signaling pathway [47] . Under Th1 and Th2 conditions, human MSCs most usually use IDO and its metabolites (kynurenine, quinolinic acid, and 3-hydroxy-anthranilic acid) to attenuate proliferation or to induce apoptosis of activated T cells [14] , while murine MSCs have lower IDO activity and usually use inducible nitric oxide synthase (iNOS)-mediated immunomodulation [14, 18, 48] . However, under Th17 conditions, murine MSCs do not produce nitric oxide and their immunosuppressive effects are mediated through the production of other mediators, including IDO [35] . MSCs are able to suppress generation of effector Th17 cells in IDO-dependent manner, and IDO inhibitors could be used to restore MSC suppression of Th17 differentiation [49] .
Protective and immunomodulatory role of IDO has been recently described in CCl 4 -induced liver fibrosis [50] . Increased infiltration of immune cells and increased expression of pro-inflammatory cytokines was noticed in fibrotic livers of CCl 4 -treated IDO-deficient mice. Aggravated liver fibrosis was also seen in mice that received IDO inhibitor [50] .
In line with these findings, attenuated liver fibrosis noticed in CCl 4 +MSC-treated mice (Fig. 1d and e) was accompanied with an increased serum levels of IDO and kynurenine (Fig. 2b) and reduced liver infiltration of Th17 cells (Fig. 2c) . Inhibition of IDO completely diminished MSC-mediated suppression of Th17 proliferation (Fig. 3a) and enhanced infiltration of Th17 cells in the fibrotic livers (Fig. 3d) . In vitro, capacity of MSCs to suppress Th17 cell-dependent induction of collagen-1 synthesis in HSCs was attenuated by IDO inhibitor (Fig. 3b) . Additionally, in vivo inhibition of IDO activity completely abrogated MSC-based suppression of Th17 cells and delineate antifibrotic effects of MSCs (Fig. 4) , suggesting important role of IDO for MSCmediated suppression of Th17-driven liver fibrosis. Indoleamine 2,3-dioxygenase has been identified as a critical molecular switch that stimulates immunosuppressive properties of IL-10 producing Tregs and simultaneously blocks re-programming of Tregs into IL-17 producing effector T cells [47] . IDO inhibition or genetic deletion led to the reduced generation of Tregs and an increase in Th17 differentiation both in vitro and in vivo [47] . Accordingly, we found that MSC-CM induced proliferation of IL-10 producing CD4 + FoxP3 + Tregs (Fig. 3a) , a phenomenon that was completely abrogated by IDO inhibitor (Fig. 3a) . We propose that MSCs produce IDO, which suppress proliferation of Th17 cells and their infiltration in fibrotic livers, reduce IL-17, and promote proliferation and liver infiltration of immunomodulatory IL-10 producing CD4 + T cells creating an immunosuppressive microenvironment in which HSCs due to the lack of IL-17-dependent activation reduce production of collagen-1, 
